Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

16.06
-0.1500-0.93%
Post-market: 16.060.00000.00%17:40 EDT
Volume:531.20K
Turnover:8.56M
Market Cap:826.98M
PE:7.26
High:16.25
Open:16.21
Low:16.00
Close:16.21
52wk High:21.03
52wk Low:9.16
Shares:51.49M
Float Shares:21.84M
Volume Ratio:1.60
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.21
EPS(LYR):2.06
ROE:50.17%
ROA:0.76%
PB:2.85
PE(LYR):7.80

Loading ...

Theravance Biopharma Inc - Settlement Subject to Review by U.S. Department of Justice and Federal Trade Commission - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance, Viatris settle Yupelri patent suit, allow Mankind generic launch in 2039

Reuters
·
Mar 31

Theravance Biopharma Is Maintained at Hold by TD Cowen

Dow Jones
·
Mar 23

Theravance Biopharma price target raised to $15 from $13 at TD Cowen

TIPRANKS
·
Mar 23

Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance

TIPRANKS
·
Mar 23

Theravance Biopharma Price Target Maintained With a $21.00/Share by BTIG

Dow Jones
·
Mar 20

Theravance Biopharma investors face litigation after 26% stock plunge

Reuters
·
Mar 19

Ireland's Theravance Biopharma Q4 revenue misses expectations

Reuters
·
Mar 19

Theravance Biopharma Q4 Operating Income USD 20.012 Million

Reuters
·
Mar 19

Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate

Benzinga
·
Mar 19

Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10

TIPRANKS
·
Mar 19

Theravance Biopharma Q4 EPS USD 1.15

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Revenue USD 45.9 Million VS. Ibes Estimate USD 58.5 Million (Corrects Amount)

THOMSON REUTERS
·
Mar 19

Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million VS. Ibes Estimate USD 58.3 Million

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million (Removes Reference to Estimate)

THOMSON REUTERS
·
Mar 19

Theravance Biopharma SVP, Comm & Medical Affairs Rhonda Farnum disposes of USD 432,167 in common shares

Reuters
·
Mar 19

Theravance Biopharma options imply 3.2% move in share price post-earnings

TIPRANKS
·
Mar 06

Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss

TIPRANKS
·
Mar 05

B. Riley Downgrades Theravance Biopharma to Neutral From Buy, Adjusts Price Target to $14 From $28

MT Newswires Live
·
Mar 04

Theravance Biopharma Inc : Btig Cuts Target Price to $21 From $40

THOMSON REUTERS
·
Mar 04